News Release

ECOG-ACRIN and PrECOG announce multiple presentations at ASH 2024

Meeting Announcement

ECOG-ACRIN Cancer Research Group

Researchers with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and PrECOG, LLC, will present a variety of abstracts that aim to improve treatments for patients with lymphomas and acute leukemias at the 66th American Society of Hematology (ASH) Meeting & Exposition. The meeting is set to occur in San Diego, California, and virtually December 7 - 10, 2024.  

Promising results from a phase 2 study (PrE0905) in patients with acute myeloid leukemia and new data from the practice-changing E1910 phase 3 trial are among the highlights. Results from the E1910 trial led to an FDA approval in June 2024 after it found that adding the immunotherapy drug blinatumomab to standard front-line consolidation chemotherapy keeps most patients with B-cell acute lymphoblastic leukemia in remission and improves their survival.  

Details for the presentations are below, listed by type and date. Times are shown in Pacific Time.  

New Data from the Practice-Changing E1910 Trial by ECOG-ACRIN 

Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial 
Presenter: Nikolai A. Podoltsev, MD, PhD (Yale University) 
Poster Abstract 4211 in Session 613 
Date and Time: Monday, December 9, 2024, 6:00 - 8:00 PM 
Location: San Diego Convention Center, Halls G-H 

Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial 
Presenter: Michaela Liedtke, MD (Stanford University)  
Oral Abstract 779 in Session 732 
Date and Time: Monday, December 9, 10:30 AM - 12:00 PM 
Presentation Time: 11:30 AM 
Location: San Diego Convention Center, Room 6A 

EBF1 Activity Controls Leukemia Sensitivity to Inotuzumab Ozogamicin 
Presenter: Carolin S. Escherich, MD (St. Jude Children’s Research Hospital) 
Oral Abstract 830 in Session 605 
Date and Time: Monday, December 9, 2:45 - 4:15 PM 
Presentation Time: 3:00 PM 
Location: San Diego Convention Center, Ballroom 20 C-D 

Trial Results 

Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Patients ≤ 70 Years Old with Mantle Cell Lymphoma: Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181 
Presenter: Nina D. Wagner-Johnston, MD (Johns Hopkins University) 
Oral Abstract 236 in Session 623 
Date and Time: Saturday, December 7, 2:00 - 3:30 PM 
Presentation Time: 2:15 PM 
Location: Marriott Marquis San Diego Marina, Grand Ballroom 11-13 

Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Pre0905 Study in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)
Presenter: Selina M. Luger, MD (University of Pennsylvania) 
Oral Abstract 221 in Session 617 
Date and Time: Saturday, December 7, 2:00 - 3:30 PM 
Presentation Time: 3:00 PM 
Location: Manchester Grand Hyatt San Diego, Seaport Ballrooms E-F-G-H 

Other New Data from ECOG-ACRIN Trials 

PKCδ-Mediated Phosphorylation of CD25 Initiates Feedback Control of Oncogenic Tyrosine Kinases in Acute Lymphoblastic Leukemia 
Presenter: Ruifeng Sun, BS (Yale University) 
Oral Abstract 632 in Session 614 
Date and Time: Sunday, December 8, 4:30 - 6:00 PM 
Presentation Time: 4:45 PM 
Location: Marriott Marquis San Diego Marina, Grand Ballrooms 5-6 

Safety and Efficacy in Pediatric Patients with Relapsed/Refractory Classic Hodgkin Lymphoma Enrolled on an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin (E4412) 
Presenter: Christopher J. Forlenza, MD (Memorial Sloan Kettering Cancer Center) 
Poster Abstract 4427 in Session 624 
Date and Time: Monday, December 9, 2024, 6:00 - 8:00 PM 
Location: San Diego Convention Center, Halls G-H 

Presenters are available for media interviews under the ASH Meeting Embargo Policy. To schedule an interview, send an email to Diane Dragaud, Director of Communications, at communications@ecog-acrin.org.  

About ECOG-ACRIN 

The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) is a membership-based scientific organization known for advancing precision medicine and biomarker research through its leadership of major national clinical trials that integrate cutting-edge genomic approaches. Nearly 21,000 member researchers and advocates from approximately 1,400 cancer centers and community hospitals collaborate across ECOG-ACRIN’s nearly 40 scientific committees to design studies spanning the cancer care spectrum, from early detection to management of advanced disease. ECOG-ACRIN is funded primarily by the National Cancer Institute (NCI), part of the National Institutes of Health, through the National Clinical Trials Network (NCTN) and NCI Community Oncology Research Program (NCORP). To learn more, visit www.ecog-acrin.org and follow us on X/Twitter @EAonc, Facebook, LinkedIn, YouTube, and Instagram

About PrECOG 

PrECOG, LLC is a cancer research organization that designs and conducts innovative oncology studies through industry partnerships and research networks. The central focus of PrECOG is to conduct trials that align with the overall scientific mission and research goals of ECOG-ACRIN. To learn  more, visit www.precogllc.org and follow us on X/Twitter @PrECOGonc, Facebook, and LinkedIn

 


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.